https://www.cancercenter.com/breast-cancer/risk-factors/tab/triple-negative-breast-cancer-risk-factors/. [5] Pal SK et al. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627--636. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com https://www.globenewswire.com/Tracker?data=iARt7gI_BiODzCAiYWnjq__ap2Es0JRINIlSzpmhV378HJ_3JwbDwu0tk6WoELbmBhZeLqztgiO8DvUVTr4k5xTHTZ1rhxw_AHIUlQExkiFQM2K4hRRHW0BZv7YbXvpF Dr. Nicolas Dunant Patrick Barth Phone: +41 61 687 05 17 Phone: +41 61 688 44 86 Dr. Daniel Grotzky Karsten Kleine Phone: +41 61 688 31 10 Phone: +41 61 682 28 31 Nina Mählitz Nathalie Meetz Phone: +41 79 327 54 74 Phone: +41 61 687 43 05 Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Jon Kaspar Bayard Phone: +41 61 68-78503 Phone: +41 61 68-83894 e-mail: karl.mahler@roche.com e-mail: jon_kaspar.bayard@roche.com Dr. Sabine Borngräber Dr. Bruno Eschli Phone: +41 61 68-88027 Phone: +41 61 68-75284 e-mail: sabine.borngraeber@roche.com e-mail: bruno.eschli@roche.com Dr. Birgit Masjost Dr. Gerard Tobin Phone: +41 61 68-84814 Phone: +41 61 68-72942 e-mail: birgit.masjost@roche.com e-mail: gerard.tobin@roche.com Investor Relations North America Loren Kalm Dr. Lisa Tuomi Phone: +1 650 225 3217 Phone: +1 650 467 8737 e-mail: kalm.loren@gene.com e-mail: tuomi.lisa@gene.com Attachment -- 28042021_MR_ Tecentriq_ODAC_mTNBC_EN https://ml-eu.globenewswire.com/Resource/Download/293c5511-7b82-4540-9b56-9027ed37194f
(END) Dow Jones Newswires
April 27, 2021 18:25 ET (22:25 GMT)